NOTE vs GOVX vs CSGP vs NVAX vs MRNA

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). Novavax, Inc. (NVAX) offers the better valuation at 4. 0x trailing P/E, making it the more compelling value choice. Analysts rate CoStar Group, Inc. (CSGP) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 4. 0x versus CoStar Group, Inc. at 1974. 1x.

Over the past 5 years, CoStar Group, Inc.

(CSGP) delivered a total return of -61. 0%, compared to -99. 8% for FiscalNote Holdings, Inc. (NOTE). Over 10 years, the gap is even starker: MRNA returned +192. 2% versus NOTE's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CoStar Group, Inc.

(CSGP) is the lower-risk stock at 0. 69β versus FiscalNote Holdings, Inc. 's 2. 66β — meaning NOTE is approximately 287% more volatile than CSGP relative to the S&P 500. On balance sheet safety, FiscalNote Holdings, Inc. (NOTE) carries a lower debt/equity ratio of 0% versus 22% for Moderna, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -660. 2% for FiscalNote Holdings, Inc.. Over a 3-year CAGR, GOVX leads at 212. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -862. 3% for GeoVax Labs, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -869. 3% for GOVX. At the gross margin level — before operating expenses — GOVX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CSGP: 86.

7% to $61. 18.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, CoStar Group, Inc.

(CSGP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69)). FiscalNote Holdings, Inc. (NOTE) carries a higher beta of 2. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CSGP: +66. 3%, NOTE: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NOTE (Technology) and GOVX (Healthcare) and CSGP (Real Estate) and NVAX (Healthcare) and MRNA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NOTE is a small-cap quality compounder stock; GOVX is a small-cap quality compounder stock; CSGP is a mid-cap high-growth stock; NVAX is a small-cap high-growth stock; MRNA is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.